Evidence map›Paper›PMID 20164301›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2010

Reversal of prolonged dopamine inhibition of dopaminergic neurons of the ventral tegmental area.

Sudarat Nimitvilai, Mark S Brodie

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Complexes of Ghrelin GHS-R1a, GHS-R1b, and Dopamine DThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Amphetamine self-administration attenuates dopamine D2 autoreceptor function.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sudarat NimitvilaiDepartment of Physiology and Biophysics, University of Illinois at Chicago, Chicago, Illinois 60612-7342, USA.
Mark S Brodie
University of Illinois Chicago · US

Funding

Intracellular Study of Ethanol Effects on Brain NeuronsR37AA005846 · NIAAA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI APPEL, SARAH B · 2002 to 2008
$2.7M
ETHANOL/NEUROTRANSMITTER INTERACTIONS IN BRAIN NEURONSR01AA009125 · NIAAA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BRODIE, MARK S · 1992 to 2007
$1.4M
INTRACELLULAR STUDY OF ETHANOL EFFECTS ON BRAIN NEURONSR01AA005846 · NIAAA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BRODIE, MARK S · 1985 to 2011
$1.2M
NIAAA NIH HHS AA05846NIAAA NIH HHS AA09125NIAAA NIH HHS R01 AA005846NIAAA NIH HHS R01 AA009125NIAAA NIH HHS R37 AA005846
6 · The paper itself

Abstract

Drug abuse-induced plasticity of putative dopaminergic (pDAergic) ventral tegmental area (VTA) neurons may play an important role in changes in the mesocorticolimbic system that lead to the development of addiction. In the present study, extracellular recordings were used to examine time-dependent effects of dopamine (DA) on pDAergic VTA neurons in rat brain slices. Administration of DA (2.5-10 microM) for 40 min resulted in inhibition followed by partial or full reversal of that inhibition. The reduced sensitivity to DA inhibition lasted 30 to 90 min after washout of the long-term dopamine administration. The inhibition reversal was not observed with 40-min administration of the D2 agonist quinpirole (25-200 nM), so this phenomenon was not the result of desensitization induced solely by stimulation of D2 DA receptors. Inhibition reversal could be observed with the coapplication of quinpirole and the D1/D5 agonist SKF38393 [(+/-)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrobromide], suggesting a D1/D5 mechanism for the reversal. Furthermore, D1/D5 antagonists, given in the presence of prolonged DA exposure, prevented the inhibition reversal. Application of 3 microM quinpirole caused desensitization to low quinpirole concentrations that was blocked by a D1/D5 antagonist. These data suggest that coactivation of D1/D5 receptors and D2 receptors in the VTA results in desensitization of autoinhibitory D2 receptors. Prolonged increases in pDAergic tone in the VTA that may occur in vivo with drugs of abuse could reduce the regulation of firing by D2 dopamine receptor activation, producing long-term alteration in information processing related to reward and reinforcement.

Indexed as

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepineAnimalsDopamineDopamine AntagonistsDopamine D2 Receptor AntagonistsDose-Response Relationship, DrugNeuronsQuinpiroleRatsRats, Inbred F344Receptors, DopamineReceptors, Dopamine D2Reinforcement, PsychologyTime FactorsVentral Tegmental Area2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepineDopamineDopamine AntagonistsDopamine D2 Receptor AntagonistsQuinpiroleReceptors, DopamineReceptors, Dopamine D2

Identifiers

PMID20164301
PMCPMC2872954
OpenAlexW2152976206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.